PlumX Metrics
Embed PlumX Metrics

How I treat late effects in adults after allogeneic stem cell transplantation

Blood, ISSN: 0006-4971, Vol: 117, Issue: 11, Page: 3002-3009
2011
  • 112
    Citations
  • 0
    Usage
  • 141
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Clinical updates in blood and marrow transplantation in multiple myeloma

  [ILLUSTRATION OMITTED]            The process of transplantation can be conceptualized through several phases (see Figure 1). Each phase carries with it distinct considerations and management strategies

Article Description

More than 25 000 allogeneic hematopoietic stem cell transplantations (allo-HCTs) are expected to be performed worldwide in 2010, a number that has been increasing yearly. With broadening indications, more options for allo-HCT, and improvement in survival, by 2020 there may be up to half a million long-term survivors after allo-HCT worldwide. These patients have increased risks for various late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring recommendations for this patient population. The purpose of this article is to describe practical approaches to screening for and managing these late effects, with the goal of reducing preventable morbidity and mortality associated with allo-HCT.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know